PsygaBio

Company Overview

Snapshot

Founded in April 2021 by Shmuel Mandel, PsygaBio operates with 1–10 employees. The company has secured funding across one round from one investor, NFX Capital. PsygaBio is focused on drug discovery and development, leveraging natural compounds for therapeutic benefits.

Business overview

PsygaBio is a drug discovery company specializing in developing therapeutics derived from natural compounds. The company utilizes Cannasoul's proprietary analytical platform, employing a data-driven approach, specialized know-how, and a clinical trial framework to identify and develop active compounds. This process spans from mushroom cultivation and extraction to clinically approved formulations. In partnership with Cannasoul Analytics, PsygaBio aims to explore the diversity within psychedelic mushrooms to pinpoint active compounds and formulations for therapeutic applications, primarily serving the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is PsygaBio's primary focus?

PsygaBio is a drug discovery company focused on developing therapeutics derived from natural compounds, leveraging the diversity found in the psychedelic mushroom realm.

Who founded PsygaBio?

PsygaBio was co-founded by Shmuel Mandel.

When was PsygaBio founded?

PsygaBio was founded in April 2021.

What is PsygaBio's relationship with Cannasoul Analytics?

PsygaBio is a subsidiary of Cannasoul Analytics and partners with them to exploit the diversity in psychedelic mushrooms for therapeutic compound identification and formulation.

What is PsygaBio's current product development stage?

PsygaBio is currently in the R&D stage for its products, focusing on identifying and developing active compounds from natural sources.